Western blot analysis of HT-29 cells, untreated (-) or treated with combinations of the following treatments as indicated: Z-VAD(OMe)-FMK #60332 (Z-VAD, 20 μM, added 30 min prior to other compounds; +), human TNF-α #8902 (hTNF-α, 20 ng/ml, 7 hr; +), SM-164 (100 nM, 7 hr; +), and necrostatin-1s (Nec-1s, indicated concentrations, 7 hr), using Phospho-RIP (Ser166) (D1L3S) Rabbit mAb #65746 (upper), RIP (D94C12) XP® Rabbit mAb #3493 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Chemical structure of Necrostatin-1s.
Necrostatin-1s is supplied as a lyophilized powder. For a 20 mM stock, reconstitute 5 mg of powder in 900 μl of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||277.7 g/mol|
|Solubility||Soluble in DMSO at 25 mg/ml.|
Necrostatin-1s, also known as Nec-1s or 7-Cl-O-Nec-1, is a potent and selective inhibitor of necroptosis. This analog of Necrostatin-1 (Nec-1) has been shown to be a specific receptor-interacting protein kinase (RIPK) 1 inhibitor that is metabolically more stable than the other variants (1). Research studies have found that Nec-1s is more selective than Nec-1 and Nec-1i (inactive variant) due to the fact that both molecules have an inhibitory affect on indoleamine 2,3-dioxygenase (IDO), a potent immunosuppressive molecule (2). Evidence also suggests that Nec-1s is around two-times more effective at RIPK1 inhibition than Nec-1 (IC50 = 210 nM vs. 494 nM) (1).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.